Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells

SET7/9 is a protein lysine methyltransferases (PLMTs or PKMTs) which methylates both histone H3K4 and non-histone proteins including transcriptional factors, tumor suppressors, and membrane-associated receptors. Methylation of these proteins alters protein activity and leads to changes in cellular behavior and a series of biological processes. This study aims to investigate the role of SET7/9 in human acute myeloid leukemia (AML) and non-small-cell lung cancer (NSCLC). We examined the expression of SET7/9 in AML cells and NSCLC cells and detected the methylation status of the SET7/9 promoter region. To evaluate the effect of SET7/9 expression changes on cell apoptosis, cell apoptosis rates were determined after SET7/9 overexpression or down-regulation. Our results showed that SET7/9 induces apoptosis of AML cells and inhibits apoptosis of NSCLC cells, suggesting differential effects of SET7/9 on cellular apoptosis and carcinogenesis depending on different cancer types and genetic contexts. Furthermore, we also demonstrated that SET7/9 suppresses cell apoptosis via modulation of E2F1 under circumstance of p53 deficiency in NSCLC cells.

[1]  Shu-jun Liu,et al.  Involvement of Histone Lysine Methylation in p21 Gene Expression in Rat Kidney In Vivo and Rat Mesangial Cells In Vitro under Diabetic Conditions , 2016, Journal of diabetes research.

[2]  Yuanyuan Chen,et al.  Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma , 2016, PloS one.

[3]  M. Montenegro,et al.  Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis , 2016, Oncogene.

[4]  Hui Guo,et al.  SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer , 2016, Tumor Biology.

[5]  K. Kojima,et al.  Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression , 2015, Oncotarget.

[6]  Shuying He,et al.  Lysine Methyltransferase SETD7 (SET7/9) Regulates ROS Signaling through mitochondria and NFE2L2/ARE pathway , 2015, Scientific Reports.

[7]  G. Melino,et al.  KMT Set7/9 affects genotoxic stress response via the Mdm2 axis , 2015, Oncotarget.

[8]  G. Melino,et al.  KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress , 2014, Cell Death and Differentiation.

[9]  E. Ferrando-May,et al.  SET7/9-dependent methylation of ARTD1 at K508 stimulates poly-ADP-ribose formation after oxidative stress , 2013, Open Biology.

[10]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[11]  M. Dong,et al.  Lysine methylation of FOXO3 regulates oxidative stress‐induced neuronal cell death , 2012, EMBO reports.

[12]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[13]  R. Trievel,et al.  Substrate and product specificities of SET domain methyltransferases , 2011, Epigenetics.

[14]  S. Campaner,et al.  The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. , 2011, Molecular cell.

[15]  U. Oppermann,et al.  Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein , 2011, The EMBO journal.

[16]  W. Gu,et al.  Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1) , 2011, Proceedings of the National Academy of Sciences.

[17]  C. Robson,et al.  Regulation of the androgen receptor by SET9-mediated methylation , 2010, Nucleic acids research.

[18]  I. Talianidis,et al.  Lysine methylation regulates E2F1-induced cell death. , 2010, Molecular cell.

[19]  C. Allis,et al.  Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.

[20]  N. L. Thangue,et al.  Lysine methylation regulates the pRb tumour suppressor protein , 2010, Oncogene.

[21]  K. Helin,et al.  Histone methyltransferases in cancer. , 2010, Seminars in cell & developmental biology.

[22]  D. Baltimore,et al.  Regulation of NF-κB activity through lysine monomethylation of p65 , 2009, Proceedings of the National Academy of Sciences.

[23]  M. Chance,et al.  Regulation of NF κB by NSD1/FBXL11-dependent reversible lysine methylation of p65 , 2009 .

[24]  S. Jacobsen,et al.  SET7/9 mediated methylation of non-histone proteins in mammalian cells , 2009, Epigenetics.

[25]  S. Jacobsen,et al.  Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells , 2009, Proceedings of the National Academy of Sciences.

[26]  Xiaodong Cheng,et al.  Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. , 2008, Molecular cell.

[27]  Hong Lei,et al.  Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. , 2008, Molecular cell.

[28]  L. Stark,et al.  Nucleolar Sequestration of RelA (p65) Regulates NF-κB-Driven Transcription and Apoptosis , 2005, Molecular and Cellular Biology.

[29]  Natalia Meani,et al.  Molecular signature of retinoic acid treatment in acute promyelocytic leukemia , 2005, Oncogene.

[30]  Paul Tempst,et al.  Regulation of p53 activity through lysine methylation , 2004, Nature.

[31]  Elisabeth Scheer,et al.  Gene-specific modulation of TAF10 function by SET9-mediated methylation. , 2004, Molecular cell.

[32]  M. Martinka,et al.  Mutations of the ING1 tumor suppressor gene detected in human melanoma abrogate nucleotide excision repair. , 2004, International journal of oncology.

[33]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[35]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[36]  A. Gartel,et al.  The Role of the Cyclin-dependent Kinase Inhibitor p 21 in Apoptosis 1 , 2002 .

[37]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[38]  D. Reinberg,et al.  Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. , 2002, Genes & development.

[39]  C. Allis,et al.  Methylation of Histone H4 at Arginine 3 Facilitating Transcriptional Activation by Nuclear Hormone Receptor , 2001, Science.

[40]  R. Willemze,et al.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.

[41]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[42]  P. Watson,et al.  Suppression of ING1 expression in sporadic breast cancer , 1999, Oncogene.

[43]  I. Garkavtsev,et al.  Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor , 1997, Molecular and cellular biology.

[44]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[45]  R. Ueda,et al.  Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[47]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.